^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

    Published date:
    04/10/2021
    Excerpt:
    Patients aged 18 years...and histologically confirmed CD20-positive...were randomly assigned....Copanlisib plus rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab.
    DOI:
    https://doi.org/10.1016/S1470-2045(21)00145-5
    Trial ID:
    CHRONOS-3
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

    Excerpt:
    ...Patients must be CD20 positive....
    Trial ID:
    FIL_Copa-RB